Empagliflozin

Adults with type 1 diabetes spent more time in range with empagliflozin 2.5 mg or 5 mg as an adjunctive therapy to hybrid closed-loop insulin therapy compared with placebo, according to a speaker.

Effects of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) on cardiac structure, function and circulating biomarkers in people with CV risk factors without diabetes.

As part of the 2022 Year in Review, Cardiology Today compiled a list of selected drugs and devices related to the specialty that were newly approved or cleared. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omissions. Appearance of a drug or device does not constitute any endorsement by Cardiology Today, its editors, publisher or editorial board. – The Editors

Empagliflozin on top of guideline recommended therapy improved CV and renal outcomes in HF with reduced ejection fraction, regardless of whether the cause of HF was ischemic or not, a study found.

Healio and Cardiology Today have aggregated a list of the top headlines of 2022 in heart failure and transplantation.

Effect of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) on kidney disease progression or CV death vs. placebo in adults with preexisting CKD.

A phase 3 trial of empagliflozin demonstrated statistically significant HbA1c reduction among children and adolescents aged 10 to 17 years with type 2 diabetes, according to a press release from Eli Lilly.

Treatments for type 1 diabetes must be tailored to the heterogeneity of disease physiology among patients, moving beyond population-based HbA1c measures to individualized glycemic time in targets, according to a speaker.

The safety and efficacy of empagliflozin to treat HF was similar in Black and white patients, despite Black patients being at higher risk for HF, researchers reported.

CHICAGO — In people without diabetes or significant HF, 6 months of empagliflozin treatment was not associated with any meaningful changes in cardiac remodeling indices compared with placebo, according to data from the EMPA-HEART 2 study.